Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In Vitro
- 1 August 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (8) , 2825-30
- https://doi.org/10.1128/aac.48.8.2825-2830.2004
Abstract
We have previously described an in vitro model for the evaluation of the effects of different immunomodulatory agents and immunotoxins (ITs) on cells latently infected with human immunodeficiency virus (HIV). We demonstrated that latently infected, replication-competent cells can be generated in vitro after eliminating CD25+cells with an IT. Thus, by selectively killing the productively infected cells with an anti-CD25 IT we can generate a population of latently infected cells. CD25−cells generated in this manner were treated with nucleoside analog reverse transcriptase inhibitors and subsequently activated with phytohemagglutinin in the presence of the drugs. The antiviral activities of zidovudine (ZDV), lamivudine (3TC), and abacavir (ABC) were evaluated by using this model. 3TC and ABC demonstrated significant activity in decreasing HIV production from recently infected resting cells following their activation, whereas the effect of ZDV was more modest. These results suggest that the differences in antiviral activity of nucleoside analogs on resting cells should be considered when designing drug combinations for the treatment of HIV infection. The model presented here offers a convenient alternative for evaluating the mechanism of action of new antiretroviral agents (J. Saavedra, C. Johnson, J. Koester, M. St. Claire, E. Vitteta, O. Ramilo, 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. I-59, 1997).Keywords
This publication has 49 references indexed in Scilit:
- An Anti‐CD45RO Immunotoxin Kills Latently Infected Human Immunodeficiency Virus (HIV) CD4 T Cells in the Blood of HIV‐Positive PersonsThe Journal of Infectious Diseases, 2002
- Twice‐Daily Triple Nucleoside Intensification Treatment with Lamivudine‐Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET StudyThe Journal of Infectious Diseases, 2001
- Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4 + T CellsScience, 1999
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- The Use of Cyclosporine, FK506, and SDZ NIM811 to Prevent CD25 Quiescent Peripheral Blood Mononuclear Cells from Producing Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.Journal of Clinical Investigation, 1993
- Inhibition of HIV Infection of Resting Peripheral Blood Lymphocytes by NucleosidesAIDS Research and Human Retroviruses, 1992
- HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structureCell, 1990